211 related articles for article (PubMed ID: 22384256)
1. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
Cuesta-Domínguez Á; Ortega M; Ormazábal C; Santos-Roncero M; Galán-Díez M; Steegmann JL; Figuera Á; Arranz E; Vizmanos JL; Bueren JA; Río P; Fernández-Ruiz E
PLoS One; 2012; 7(2):e32451. PubMed ID: 22384256
[TBL] [Abstract][Full Text] [Related]
2. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Lacronique V; Boureux A; Monni R; Dumon S; Mauchauffé M; Mayeux P; Gouilleux F; Berger R; Gisselbrecht S; Ghysdael J; Bernard OA
Blood; 2000 Mar; 95(6):2076-83. PubMed ID: 10706877
[TBL] [Abstract][Full Text] [Related]
3. The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion.
Mayumi A; Tomii T; Kanayama T; Mikami T; Tanaka K; Ueno H; Yoshida H; Kato I; Kawamura M; Nakahata T; Takita J; Hosoi H; Imamura T
Cancer Gene Ther; 2022 Dec; 29(12):1930-1938. PubMed ID: 35879405
[TBL] [Abstract][Full Text] [Related]
4. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
6. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
7. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
[TBL] [Abstract][Full Text] [Related]
8. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
[TBL] [Abstract][Full Text] [Related]
9. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
11. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
13. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
14. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Samanta A; Perazzona B; Chakraborty S; Sun X; Modi H; Bhatia R; Priebe W; Arlinghaus R
Leukemia; 2011 Mar; 25(3):463-72. PubMed ID: 21183952
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
[TBL] [Abstract][Full Text] [Related]
17. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
18. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
19. BCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.
Cuesta-Domínguez Á; León-Rico D; Álvarez L; Díez B; Bodega-Mayor I; Baños R; Martín-Rey MÁ; Santos-Roncero M; Gaspar ML; Martín-Acosta P; Almarza E; Bueren JA; Río P; Fernández-Ruiz E
J Pathol; 2015 Jun; 236(2):219-28. PubMed ID: 25664618
[TBL] [Abstract][Full Text] [Related]
20. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.
Funakoshi-Tago M; Tago K; Sumi K; Abe M; Aizu-Yokota E; Oshio T; Sonoda Y; Kasahara T
J Biol Chem; 2009 May; 284(19):12680-90. PubMed ID: 19289461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
